287 filings
Page 2 of 15
8-K
l4tjz0esqj
9 Jun 23
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
yvnq5426i
7 Jun 23
FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy
9:00am
DEFA14A
y66g1 rkm0key96d1c
31 May 23
Additional proxy soliciting materials
9:00am
8-K
9zgr2puf6q
18 May 23
FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia
7:35am
8-K
ecs o9y6u0n
8 May 23
FibroGen Reports First Quarter 2023 Financial Results
4:06pm
8-K
m7wjdvh
1 May 23
Entry into a Material Definitive Agreement
4:48pm
ARS
y7fhxgabogim4 ba
27 Apr 23
Annual report to shareholders
4:17pm
DEFA14A
52vim7h0s
27 Apr 23
Additional proxy soliciting materials
4:10pm
424B5
bbkrm4 aq9s8ye9yyck
27 Feb 23
Prospectus supplement for primary offering
4:40pm
8-K
4e0myyz1xh2465jq4
27 Feb 23
FibroGen Reports Fourth Quarter and Full Year 2022 Financial Results
4:06pm
8-K
dn20cjru
7 Nov 22
FibroGen Reports Third Quarter 2022 Financial Results
4:06pm
S-8
5o6erdhyose
8 Aug 22
Registration of securities for employees
5:22pm
S-3ASR
v359218 l5
8 Aug 22
Automatic shelf registration
5:12pm
8-K
g28tq 5kz7r
8 Aug 22
FibroGen Reports Second Quarter 2022 Financial Results
4:07pm
8-K
ligj8 l6c93duj
17 Jun 22
Submission of Matters to a Vote of Security Holders
5:20pm